Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,078,098
  • Shares Outstanding, K 102,676
  • Annual Sales, $ 131,160 K
  • Annual Income, $ -95,500 K
  • EBIT $ -166 M
  • EBITDA $ -164 M
  • 60-Month Beta -1.27
  • Price/Sales 8.08
  • Price/Cash Flow N/A
  • Price/Book 2.41

Options Overview Details

View History
  • Implied Volatility 113.27% (+8.75%)
  • Historical Volatility 100.16%
  • IV Percentile 39%
  • IV Rank 14.16%
  • IV High 613.84% on 10/23/25
  • IV Low 30.71% on 09/04/25
  • Expected Move (DTE 35) 1.53 (14.57%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 22,296
  • Volume Avg (30-Day) 4,782
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 63,357
  • Open Int (30-Day) 56,144
  • Expected Range 8.97 to 12.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.15
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.18
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +78.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.28 +26.01%
on 12/17/25
11.65 -10.39%
on 01/13/26
+2.19 (+26.55%)
since 12/16/25
3-Month
6.90 +51.30%
on 10/30/25
11.65 -10.39%
on 01/13/26
+2.97 (+39.76%)
since 10/16/25
52-Week
5.64 +85.27%
on 08/06/25
13.53 -22.84%
on 01/28/25
-1.96 (-15.81%)
since 01/16/25

Most Recent Stories

More News
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate...

DAWN : 10.44 (-0.57%)
Day One Completes Acquisition of Mersana Therapeutics

BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies...

MRSN : 29.08 (+0.14%)
DAWN : 10.44 (-0.57%)
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 10.44 (-0.57%)
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial  77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off...

DAWN : 10.44 (-0.57%)
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 10.44 (-0.57%)
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid...

DAWN : 10.44 (-0.57%)
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval...

DAWN : 10.44 (-0.57%)
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million ...

DAWN : 10.44 (-0.57%)
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 10.44 (-0.57%)
Day One Biopharmaceuticals Reprices Stock Options for Retention

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Day One Biopharmaceuticals...

DAWN : 10.44 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One Biopharmaceuticals Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 11.86
2nd Resistance Point 11.52
1st Resistance Point 11.01
Last Price 10.44
1st Support Level 10.16
2nd Support Level 9.82
3rd Support Level 9.31

See More

52-Week High 13.53
Fibonacci 61.8% 10.51
Last Price 10.44
Fibonacci 50% 9.58
Fibonacci 38.2% 8.65
52-Week Low 5.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar